Choroidal Melanoma

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Jill Hopkins, MD, of Aura Biosciences discusses a phase 3 program in ocular oncology.

Aura Biosciences announced that it has received an agreement from the FDA under a special protocol assessment for the design of a phase 3 trial assessing belzupacap sarotalocan, according to a press release.

A 58-year-old white woman was referred to the retina service at the New England Eye Center for a new right eye choroidal mass.

Belzupacap sarotalocan via suprachoroidal administration demonstrated positive interim phase 2 safety and efficacy data at an average of 9 months follow-up for the treatment of early-stage choroidal melanoma.

CHICAGO — AU-011 helped preserve vision in patients with early-stage choroidal melanoma, according to a study presented at the American Academy of Ophthalmology meeting.

Aura Biosciences announce positive visual acuity results from a phase 1b/2 trial of its cancer drug AU-011 in patients with choroidal melanoma.

In the past, only clinical factors were used to judge “risky nevi,” but imaging modalities are predictive tools for identifying choroidal nevus risk factors for growth to melanoma, according to Carol L. Shields, MD.

WAILEA, Hawaii — The notion that all pigmentation in the eye is melanoma is a “rumor,” according to a speaker at Hawaiian Eye 2021.

A phase 1b/2 open-label clinical trial of patients with choroidal melanoma treated with AU-011 showed a statistically significant reduction in tumor growth rate and favorable preliminary vision, according to a speaker.

The first patient has been dosed in a phase 2 clinical trial investigating safety and efficacy of suprachoroidal administration of AU-011 as a potential treatment for primary choroidal melanoma, according to a press release.